Compare Stocks: ALEC, FDMT, CLYM, and DSGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$1.95 +1.2%	$1.96	$1.09 ▼ $3.40	$217.29M	0.65	931,436 shs	639,805 shs
CLYM Climb Bio	$13.88 +1.7%	$14.30	$1.54 ▼ $18.33	$797.27M	0.09	1.03 million shs	242,798 shs
DSGN Design Therapeutics	$13.01 +3.6%	$13.85	$5.28 ▼ $17.25	$813.60M	1.66	602,334 shs	122,690 shs
FDMT 4D Molecular Therapeutics	$16.07 +5.5%	$12.87	$6.96 ▼ $16.93	$886.49M	2.74	827,865 shs	284,746 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	+1.05%	-12.67%	-18.22%	+5.46%	-36.30%
CLYM Climb Bio	-2.92%	-6.32%	-21.06%	+10.89%	+490.48%
DSGN Design Therapeutics	+2.53%	-7.17%	-16.28%	-8.66%	+107.44%
FDMT 4D Molecular Therapeutics	+0.13%	+10.76%	-3.73%	+31.38%	+130.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$1.95 +1.2%	$1.96	$1.09 ▼ $3.40	$217.29M	0.65	931,436 shs	639,805 shs
CLYM Climb Bio	$13.88 +1.7%	$14.30	$1.54 ▼ $18.33	$797.27M	0.09	1.03 million shs	242,798 shs
DSGN Design Therapeutics	$13.01 +3.6%	$13.85	$5.28 ▼ $17.25	$813.60M	1.66	602,334 shs	122,690 shs
FDMT 4D Molecular Therapeutics	$16.07 +5.5%	$12.87	$6.96 ▼ $16.93	$886.49M	2.74	827,865 shs	284,746 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	+1.05%	-12.67%	-18.22%	+5.46%	-36.30%
CLYM Climb Bio	-2.92%	-6.32%	-21.06%	+10.89%	+490.48%
DSGN Design Therapeutics	+2.53%	-7.17%	-16.28%	-8.66%	+107.44%
FDMT 4D Molecular Therapeutics	+0.13%	+10.76%	-3.73%	+31.38%	+130.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.13	Hold	$3.63	85.61% Upside
CLYM Climb Bio	3.00	Buy	$26.92	94.04% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	26.87% Upside
FDMT 4D Molecular Therapeutics	2.82	Moderate Buy	$28.56	77.67% Upside

Current Analyst Ratings Breakdown

Latest ALEC, FDMT, CLYM, and DSGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/14/2026	FDMT 4D Molecular Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$20.00
9/8/2026	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$18.00 ➝ $25.00
9/8/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $30.00
9/7/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/4/2026	CLYM Climb Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/4/2026	CLYM Climb Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00 ➝ $30.00
9/3/2026	CLYM Climb Bio	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$40.00
9/3/2026	CLYM Climb Bio	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$21.00 ➝ $25.00
9/3/2026	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $32.00
8/24/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $24.00

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$21.05M	10.36	N/A	N/A	$0.28 per share	6.98
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
FDMT 4D Molecular Therapeutics	$85.21M	10.42	N/A	N/A	$8.85 per share	1.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$142.93M	-$1.10	N/A	N/A	N/A	-850.13%	-531.03%	-44.00%	11/5/2026 (Estimated)
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/11/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)

Latest ALEC, FDMT, CLYM, and DSGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/6/2026	Q2 2026	ALEC Alector	-$0.2286	-$0.21	+$0.0186	-$0.21	$1.71 million	$3.32 million
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.80	5.26	5.26
CLYM Climb Bio	N/A	31.45	31.45
DSGN Design Therapeutics	N/A	18.86	18.86
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
CLYM Climb Bio	69.76%
DSGN Design Therapeutics	56.64%
FDMT 4D Molecular Therapeutics	99.27%

Insider Ownership

Company	Insider Ownership
ALEC Alector	8.30%
CLYM Climb Bio	2.60%
DSGN Design Therapeutics	17.10%
FDMT 4D Molecular Therapeutics	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	103	111.66 million	102.39 million	Optionable
CLYM Climb Bio	29	57.44 million	55.94 million	N/A
DSGN Design Therapeutics	55	62.58 million	51.88 million	Optionable
FDMT 4D Molecular Therapeutics	196	55.24 million	50.88 million	Optionable

ALEC, FDMT, CLYM, and DSGN Headlines

Recent News About These Companies

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 18, 2026 | marketbeat.com

4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

September 17, 2026 | seekingalpha.com

David Kirn Sells 58,333 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

September 17, 2026 | insidertrades.com

Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $810,828.70 in Stock

September 16, 2026 | marketbeat.com

4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 7.3% on Analyst Upgrade

September 16, 2026 | americanbankingnews.com

4D Molecular Therapeutics (NASDAQ:FDMT) Stock Rating Upgraded by Cantor Fitzgerald

September 16, 2026 | americanbankingnews.com

4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 7.3% After Analyst Upgrade

September 14, 2026 | marketbeat.com

4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded to "Overweight" at Cantor Fitzgerald

September 14, 2026 | marketbeat.com

4DMT Announces New Employment Inducement Grants

September 11, 2026 | globenewswire.com

Opaleye Management Inc. Has $4.45 Million Holdings in 4D Molecular Therapeutics, Inc. $FDMT

September 11, 2026 | marketbeat.com

Bank of New York Mellon Corp Purchases Shares of 152,337 4D Molecular Therapeutics, Inc. $FDMT

September 9, 2026 | marketbeat.com

68,349 Shares in 4D Molecular Therapeutics, Inc. $FDMT Purchased by Man Group plc

September 4, 2026 | marketbeat.com

4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 6.2% - Time to Sell?

August 31, 2026 | marketbeat.com

BlackRock Inc. Invests $60.46 Million in 4D Molecular Therapeutics, Inc. $FDMT

August 31, 2026 | marketbeat.com

Jupiter Topco LLC Purchases New Position in 4D Molecular Therapeutics, Inc. $FDMT

August 28, 2026 | marketbeat.com

Trails Edge Capital Partners LP Buys New Stake in 4D Molecular Therapeutics, Inc. $FDMT

August 26, 2026 | marketbeat.com

4DMT to Participate in Upcoming Investor Conferences

August 25, 2026 | globenewswire.com

Parkman Healthcare Partners LLC Acquires New Holdings in 4D Molecular Therapeutics, Inc. $FDMT

August 25, 2026 | marketbeat.com

4D Molecular Therapeutics, Inc. $FDMT Stake Boosted by Bank of America Corp DE

August 25, 2026 | marketbeat.com

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Analysts

August 24, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, FDMT, CLYM, and DSGN Company Descriptions

Alector NASDAQ:ALEC

$1.95 +0.02 (+1.19%)

As of 12:38 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Climb Bio NASDAQ:CLYM

$13.88 +0.24 (+1.72%)

As of 12:37 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Design Therapeutics NASDAQ:DSGN

$13.00 +0.46 (+3.63%)

As of 12:37 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

4D Molecular Therapeutics NASDAQ:FDMT

$16.07 +0.83 (+5.46%)

As of 12:38 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALEC, FDMT, CLYM, and DSGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALEC, FDMT, CLYM, and DSGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALEC, FDMT, CLYM, and DSGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, FDMT, CLYM, and DSGN Company Descriptions

Alector NASDAQ:ALEC

Climb Bio NASDAQ:CLYM

Design Therapeutics NASDAQ:DSGN

4D Molecular Therapeutics NASDAQ:FDMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALEC, FDMT, CLYM, and DSGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALEC, FDMT, CLYM, and DSGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALEC, FDMT, CLYM, and DSGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, FDMT, CLYM, and DSGN Company Descriptions

Alector NASDAQ:ALEC

Climb Bio NASDAQ:CLYM

Design Therapeutics NASDAQ:DSGN

4D Molecular Therapeutics NASDAQ:FDMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools